In Anticipation Of Acquisition, Resverlogix Spins Out Epigenetics Platform
This article was originally published in The Pink Sheet Daily
The publicly listed Canadian biotech is prepping for a potential takeout after Phase IIb for its lead candidate by spinning out its preclinical epigenetics platform into a new private company. If Resverlogix is acquired, the newco could potentially gain a royalty from the acquirer in exchange for access to IP.
You may also be interested in...
Theravance To Split Into A Royalty Play and An R&D Company
With a pair of PDUFA dates this year, Theravance is thinking ahead how to pass potential royalties to investors while continuing to fund its pipeline. The biopharma said it would separate into two public companies: a royalty play to return cash to shareholders and an R&D pipeline story.
Deals of the Week: Ante Up For Antisense, Pharma Places Another Isis Bet
The biotech brings Roche on as its seventh biopharma partner, building on the more than $5 billion in potential partnership revenue the biotech had already amassed. If all goes as planned, Isis will add five marketed products within the next five years to the newly approved Kynamro. But Wall Street doesn’t expect Isis’ revenues to increase much anytime soon. Plus more notable deals this week…
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
Termination of the development program for dalcetrapib creates more doubt about the class of CETP inhibitors, long viewed with ambivalence. But important differences in how the drug works compared to rivals leaves room for some to hold out hope for CETP inhibition and the HDL hypothesis in general.